MAIA Biotechnology
CompanyUnited States
MAIA Biotechnology develops one asset, in phase 3 (Ateganosine in non-small cell lung cancer). Mostly small molecule acting on TERT, telomerase and telomere maintenance and DNA damage response; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 0
- Signals
Pipeline
1Telomere-targeting agent that induces telomeric DNA damage in cancer cells
Phase 3, Small molecule, TERT, Telomerase and telomere maintenance, non-small cell lung cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Similar companies6